✦ LIBER ✦

Interferon alfa-2a treatment for chronic hepatitis C without cirrhosis and its effects on the incidence of hepatocellular carcinoma

✍ Scribed by Katsuhisa Omagari; Nobuhiro Ikuno; Takeo Imanishi; Kenji Hayashida; Ken-ichiro Inoue; Masahiro Senju; Norihiko Mori; Toshiro Tanaka; Koji Nakamuta; Hidetoshi Oda; Atsushi Minamino; Kohei Komatsu; Yasuko Nomura; Shigeru Kohno

Publisher: Springer
Year: 1998
Tongue: English
Weight: 463 KB
Volume: 4
Category: Article
ISSN: 1341-321X
DOI: 10.1007/bf02490168

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for hepatocellular carcinom

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

✍ Akinori Kasahara; Norio Hayashi; Kiyoshi Mochizuki; Masahide Takayanagi; Kentaro 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with

The effect of retreatment with interfero

The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C

✍ Hidenori Toyoda; Takashi Kumada; Satoshi Nakano; Isao Takeda; Keiichi Sugiyama; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

BACKGROUND. Interferon (IFN) has been reported to have beneficial long term effects that reduce the occurrence of hepatocellular carcinoma (HCC), even in patients who do not have complete responses to IFN. The authors evaluated the effect of retreatment with IFN-␣ on the long term prognoses of those

Effect of interferon therapy on the inci

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients

✍ Hideo Tanaka; Hideaki Tsukuma; Akinori Kasahara; Norio Hayashi; Harumasa Yoshiha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 121 KB 👁 3 views

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may